
Jan 6 (Reuters) - Johnson & Johnson JNJ.N:
JOHNSON & JOHNSON SUBMITS APPLICATION TO THE EUROPEAN MEDICINES AGENCY FOR TECVAYLI®▼ (TECLISTAMAB) IN COMBINATION WITH DARZALEX® (DARATUMUMAB) SUBCUTANEOUS FORMULATION FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Source text: [ID:]